<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="Medicine: Vaccination and Immunization : Medicine and Health Sciences :" exact="Infectious" post="Diseases : Infectious Disease Control: Vaccines : Medicine and"/>
 <result pre="Vaccination and Immunization : Medicine and Health Sciences : Infectious" exact="Diseases" post=": Infectious Disease Control: Vaccines : Medicine and Health"/>
 <result pre="Immunization : Medicine and Health Sciences : Infectious Diseases :" exact="Infectious" post="Disease Control: Vaccines : Medicine and Health Sciences :"/>
 <result pre=": Medicine and Health Sciences : Infectious Diseases : Infectious" exact="Disease" post="Control: Vaccines : Medicine and Health Sciences : Epidemiology:"/>
 <result pre="Disease Control: Vaccines : Medicine and Health Sciences : Epidemiology:" exact="Infectious" post="Disease Epidemiology : Medicine and Health Sciences : Infectious"/>
 <result pre="Control: Vaccines : Medicine and Health Sciences : Epidemiology: Infectious" exact="Disease" post="Epidemiology : Medicine and Health Sciences : Infectious Diseases:"/>
 <result pre="Epidemiology: Infectious Disease Epidemiology : Medicine and Health Sciences :" exact="Infectious" post="Diseases: Infectious Disease Epidemiology : People and Places :"/>
 <result pre="Disease Epidemiology : Medicine and Health Sciences : Infectious Diseases:" exact="Infectious" post="Disease Epidemiology : People and Places : Geographical Locations:"/>
 <result pre="Epidemiology : Medicine and Health Sciences : Infectious Diseases: Infectious" exact="Disease" post="Epidemiology : People and Places : Geographical Locations: Africa"/>
 <result pre="Public and Occupational Health : Medicine and Health Sciences :" exact="Infectious" post="Diseases : Viral Diseases: Yellow Fever : Medicine and"/>
 <result pre="and Occupational Health : Medicine and Health Sciences : Infectious" exact="Diseases" post=": Viral Diseases: Yellow Fever : Medicine and Health"/>
 <result pre="Health : Medicine and Health Sciences : Infectious Diseases :" exact="Viral" post="Diseases: Yellow Fever : Medicine and Health Sciences :"/>
 <result pre="and Health Sciences : Infectious Diseases : Viral Diseases: Yellow" exact="Fever" post=": Medicine and Health Sciences : Pathology and Laboratory"/>
 <result pre="Immunity : Medicine and Health Sciences : Immunology: Immunity Eliminating" exact="yellow fever" post="epidemics in Africa: Vaccine demand forecast and impact modelling"/>
 <result pre="Vaccine demand forecast and impact modelling Modelling the elimination of" exact="yellow fever" post="epidemics in africa http://orcid.org/0000-0001-6462-7185JeanKévinData curationFormal analysisMethodologySoftwareValidationVisualizationWriting – original draftWriting"/>
 <result pre="des Arts et Métiers, Paris, France[3], MRC Centre for Global" exact="Infectious" post="Disease Analysis, Department of Infectious Disease Epidemiology, Imperial College,"/>
 <result pre="Arts et Métiers, Paris, France[3], MRC Centre for Global Infectious" exact="Disease" post="Analysis, Department of Infectious Disease Epidemiology, Imperial College, St"/>
 <result pre="France[3], MRC Centre for Global Infectious Disease Analysis, Department of" exact="Infectious" post="Disease Epidemiology, Imperial College, St Mary’s Campus, Norfolk Place"/>
 <result pre="MRC Centre for Global Infectious Disease Analysis, Department of Infectious" exact="Disease" post="Epidemiology, Imperial College, St Mary’s Campus, Norfolk Place London,"/>
 <result pre="Imperial College, St Mary’s Campus, Norfolk Place London, United Kingdom[4]," exact="Infectious" post="Hazard Management, World Health Organization, Geneva, Switzerland[5], Robert Koch-Institut,"/>
 <result pre="Organization, Geneva, Switzerland[5], Robert Koch-Institut, Nordufer, Berlin, Germany[6], Arbovirus and" exact="viral" post="haemorrhagic fever unit, Institut Pasteur de Dakar, Dakar, SenegalAlthouseBenjaminEditor[],"/>
 <result pre="fever unit, Institut Pasteur de Dakar, Dakar, SenegalAlthouseBenjaminEditor[], Institute for" exact="Disease" post="Modeling, UNITED STATES KJ, AH and TG received personal"/>
 <result pre="credited.pntd.0008304.pdf Abstract Background To counter the increasing global risk of" exact="Yellow fever" post="(YF), the World Health Organisation initiated the Eliminate Yellow"/>
 <result pre="Yellow fever (YF), the World Health Organisation initiated the Eliminate" exact="Yellow fever" post="Epidemics (EYE) strategy. Estimating YF burden, as well as"/>
 <result pre="variants to estimate YF burden in sub-Saharan Africa, assuming all" exact="infections" post="stem from either the sylvatic or the urban cycle"/>
 <result pre="the local presence of any YF reported event in 34" exact="African" post="countries. We calibrated under-reporting using independent estimates of transmission"/>
 <result pre="eight years would avert an estimated 9,900,000 (95% CI 7,000,000–13,400,000)" exact="infections" post="and 480,000 (180,000–1,140,000) deaths over the lifetime of vaccinees,"/>
 <result pre="campaigns are begun or continued with the aim to eliminate" exact="yellow fever" post="(YF) epidemics in several countries, estimating disease burden and"/>
 <result pre="to eliminate yellow fever (YF) epidemics in several countries, estimating" exact="disease" post="burden and vaccine impact is timely. We developed two"/>
 <result pre="niche model fitted to known records of YF in 34" exact="African" post="countries and calibrated using serological survey data. Local numbers"/>
 <result pre="in 34 African countries and calibrated using serological survey data." exact="Local" post="numbers of YF infections and deaths were derived while"/>
 <result pre="and calibrated using serological survey data. Local numbers of YF" exact="infections" post="and deaths were derived while accounting for time-varying vaccination"/>
 <result pre="current international strategy to counter the increasing global risk of" exact="yellow fever." post="Funding The Bill &amp;amp; Melinda Gates Foundation (grant numbers"/>
 <result pre="fig-count: table-count: page-count: Data Availability Data on presence of any" exact="yellow fever" post="report between 1984 and 2013 used in the main"/>
 <result pre="Recent outbreaks in Angola, Nigeria and Brazil have shown that" exact="yellow fever" post="(YF) remains a significant public health threat [1,2]. The"/>
 <result pre="significant public health threat [1,2]. The epidemics of Zika and" exact="chikungunya" post="in Latin America have also highlighted the risks of"/>
 <result pre="the World Health Organisation (WHO) adopted a strategy to Eliminate" exact="Yellow fever" post="Epidemics (EYE) by 2026. This strategy aims to prevent"/>
 <result pre="[5]. The EYE strategy largely relies on, but is not" exact="limited" post="to, scale-up of vaccination. Vaccination activities considered in the"/>
 <result pre="cohorts or unvaccinated sub-populations, and reactive campaigns in outbreak situations." exact="Local" post="assessment of YF transmission intensity is key for the"/>
 <result pre="these vaccination activities; particularly since the supply of vaccine is" exact="limited" post="as seen during the 2016 Angola outbreak [6,7]. Vaccine"/>
 <result pre="the virus within the wildlife reservoir (non-human primates) and spill-over" exact="infection" post="may occur for humans living or working in jungle"/>
 <result pre="the virus between humans. Population (‘herd’) immunity (whether via natural" exact="infection" post="or vaccination) will be expected to modify transmission intensity"/>
 <result pre="human populations. Recently, two models quantifying the incidence of the" exact="disease" post="in Africa or worldwide have been used to derive"/>
 <result pre="for vaccination impact [9,10]. Both assumed a constant force of" exact="infection" post="over time. A static force of infection, unaffected by"/>
 <result pre="the sylvatic YF transmission cycle to be predominant in the" exact="Brazilian" post="epidemiological context [12]. However, there is a consensus that"/>
 <result pre="the relative contribution of each is unknown [5,13]. In the" exact="absence of" post="estimates of the relative contribution of zoonotic versus human-to-human"/>
 <result pre="EYE strategy, evaluating vaccine demand and impact in terms of" exact="infections" post="and mortality averted. Methods The Yellow Fever burden model"/>
 <result pre="in terms of infections and mortality averted. Methods The Yellow" exact="Fever" post="burden model [9] was developed to estimate YF disease"/>
 <result pre="Yellow Fever burden model [9] was developed to estimate YF" exact="disease" post="burden and vaccine impact across 34 African countries at"/>
 <result pre="to estimate YF disease burden and vaccine impact across 34" exact="African" post="countries at high or moderate risk for YF [5]."/>
 <result pre="original model was developed assuming that the locally-fitted force of" exact="infection" post="(the annual probability of infection for a susceptible individual),"/>
 <result pre="that the locally-fitted force of infection (the annual probability of" exact="infection" post="for a susceptible individual), λ, was constant in time."/>
 <result pre="basic reproduction number R0, which allows the resulting force of" exact="infection" post="to vary dynamically as population-level immunity changes over time."/>
 <result pre="dynamically as population-level immunity changes over time. Model overview A" exact="complete" post="description of the model is available in S1 Appendix."/>
 <result pre="a generalized linear model (GLM) fitted to the presence or" exact="absence of" post="any reported YF event between 1984 and 2013 at"/>
 <result pre="probability of a report as dependent on the number of" exact="infections" post="and on the unknown rate of under-reporting (which was"/>
 <result pre="intensity, obtained by fitting 12 serological surveys performed in 11" exact="African" post="countries. The two model versions differ in the way"/>
 <result pre="of the model (FOI model) a constant, age-independent force of" exact="infection" post="(FOI) λ is fitted to each serological survey. Alternatively,"/>
 <result pre="population is reduced by vaccination but the per-capita risk of" exact="infection" post="of remaining susceptible individuals remains unchanged, always resulting in"/>
 <result pre="remains unchanged, always resulting in a non-zero number of new" exact="infections" post="with imperfect vaccination coverage. In contrast, the R0 model"/>
 <result pre="the critical vaccination coverage), then we assumed that no new" exact="infection" post="will be expected in that year. In that case,"/>
 <result pre="assumed that 12% (95% CI: 5% to 26%) of all" exact="infections" post="develop severe disease and a case fatality ratio among"/>
 <result pre="(95% CI: 5% to 26%) of all infections develop severe" exact="disease" post="and a case fatality ratio among severe cases of"/>
 <result pre="of 47% (95% CI: 31% to 62%) [18] to translate" exact="infection" post="incidence estimates into numbers of severe cases, deaths and"/>
 <result pre="an optimal sequence of PMVC implementation. For each strategy, the" exact="total" post="target population was estimated. The corresponding number of vaccine"/>
 <result pre="the model. A: presence (red) or absence (white) of any" exact="yellow fever" post="report between 1984 and 2013. B: Location, sample size"/>
 <result pre="6.2e-7 (4.5e-8–3.6e-6), Guinea-Bissau Maximum per-infection probability of detection 1.9e-5 (9.0e-6–3.8e-5)," exact="Central" post="African Republic 3.0e-5 (1.8e-5–5.1e-5), Central African Republic Vaccine efficacy"/>
 <result pre="(4.5e-8–3.6e-6), Guinea-Bissau Maximum per-infection probability of detection 1.9e-5 (9.0e-6–3.8e-5), Central" exact="African" post="Republic 3.0e-5 (1.8e-5–5.1e-5), Central African Republic Vaccine efficacy 0.952"/>
 <result pre="probability of detection 1.9e-5 (9.0e-6–3.8e-5), Central African Republic 3.0e-5 (1.8e-5–5.1e-5)," exact="Central" post="African Republic Vaccine efficacy 0.952 (0.749–0.993) 0.942 (0.671–0.993) Burden"/>
 <result pre="of detection 1.9e-5 (9.0e-6–3.8e-5), Central African Republic 3.0e-5 (1.8e-5–5.1e-5), Central" exact="African" post="Republic Vaccine efficacy 0.952 (0.749–0.993) 0.942 (0.671–0.993) Burden estimates"/>
 <result pre="2017 number of severe cases 240,000 (90,000–620,000) 70,000 (9,000–270,000) 2017" exact="total" post="number of infections 2,190,000 (1,310,000–3,710,000) 670,000 (100,000–1,790,000) 2017 total"/>
 <result pre="severe cases 240,000 (90,000–620,000) 70,000 (9,000–270,000) 2017 total number of" exact="infections" post="2,190,000 (1,310,000–3,710,000) 670,000 (100,000–1,790,000) 2017 total number of DALYs"/>
 <result pre="2017 total number of infections 2,190,000 (1,310,000–3,710,000) 670,000 (100,000–1,790,000) 2017" exact="total" post="number of DALYs lost 5,400,000 (1,900,000–13,600,000) 1,700,000 (240,000–7,000,000) Lifetime"/>
 <result pre="results of serological surveys. These detection probabilities, which encompass all" exact="infections" post="that occurred during the 1984–2013 period including asymptomatic infections,"/>
 <result pre="(Fig 2 and S3 Fig). Several provinces in Eastern and" exact="Central" post="Africa had median R0 estimates just above one—in reality"/>
 <result pre="model means it is unable to generate estimates of R0&amp;lt;1." exact="Local" post="estimates of critical vaccination coverage (CVC), the threshold above"/>
 <result pre="estimates of critical vaccination coverage (CVC), the threshold above which" exact="partial" post="vaccination coverage is expected to protect the entire population,"/>
 <result pre="provinces. Both model versions estimated vaccine efficacy at 0.95, with" exact="lower" post="bound of the 95% credibility interval surrounding 0.70 (Table"/>
 <result pre="(B) model variants. A: median estimates of the force of" exact="infection" post="(FOI), in %; B: median estimates of R0. Maps"/>
 <result pre="Comparison of directly estimated versus model-predicted transmission parameters for three" exact="external" post="serological studies. Black: direct estimate; blue: prediction of the"/>
 <result pre="of mass vaccination campaigns (that is, before 2006), but a" exact="lower" post="burden thereafter (S5 Fig). Of note, with no or"/>
 <result pre="both model variants. Fig 4 Estimated 2017 incidence of severe" exact="yellow fever" post="infection per 100,000 persons across 34 African countries. A:"/>
 <result pre="variants. Fig 4 Estimated 2017 incidence of severe yellow fever" exact="infection" post="per 100,000 persons across 34 African countries. A: FOI"/>
 <result pre="of severe yellow fever infection per 100,000 persons across 34" exact="African" post="countries. A: FOI model, B: R0 model. For the"/>
 <result pre="model, PMVCs conducted between 2005 and 2017 under the Yellow" exact="Fever" post="Initiative [19] were estimated to have already prevented 700,000"/>
 <result pre="the 2018–2026 period. Such a strategy would prevent 9,900,000 (7,000,000–13,400,000)" exact="infections" post="and 480,000 (180,000–1,140,000) deaths over the lifetime of the"/>
 <result pre="in larger number of deaths prevented at the cost of" exact="lower" post="impact per doses. Fig 5 Estimates of the effective"/>
 <result pre="for vaccination strategies. Each vaccination strategy includes all provinces from" exact="upper" post="prioritization levels (ie the strategy B consists in vaccinating"/>
 <result pre="estimates of different preventive mass vaccination (PMVCs) strategies. EYE strategy" exact="Total" post="target population (millions) Average number of doses per year"/>
 <result pre="Total target population (millions) Average number of doses per year" exact="Infections" post="prevented Deaths prevented Deaths prevented per 1,000 vaccine doses*"/>
 <result pre="644.4 83.1 15,141,000 (10,927,000–20,981,000) 736,000 (288,000–1,716,000) 1.1 (0.4–2.6) 29% (12–77%)" exact="Infections" post="and deaths prevented are calculated as the difference in"/>
 <result pre="considered strategy and a baseline scenario assuming no future PMVCs." exact="Infections" post="include asymptomatic, mild and severe infections. * assuming no"/>
 <result pre="modelling study presents updated estimates of YF burden across 34" exact="African" post="countries in terms of number of infections, severe cases,"/>
 <result pre="also estimated that PMVCs conducted since 2005 will prevent a" exact="total" post="of 3 to 6 million deaths over the lifetime"/>
 <result pre="none or maximal herd effects, respectively) do contribute to the" exact="disease" post="burden, the real impact of vaccination likely lies between"/>
 <result pre="and 2026 for PMVCs would prevent 9.89 (6.96–13.3) million YF" exact="infections" post="and thus considerably reduce the risk of international spread."/>
 <result pre="with no or maximized herd effects, respectively. The reality of" exact="yellow fever" post="transmission probably lies within these bounds. Better understanding the"/>
 <result pre="large swathes of West Africa, with more patchy presence in" exact="Central" post="and East Africa, which in turn determine the gradient"/>
 <result pre="transmission intensity are estimated by fitting serological surveys data from" exact="Central" post="and Eastern Africa. Unfortunately, high quality surveys from West"/>
 <result pre="of transmission intensity levels. Our estimates of under-reporting of the" exact="disease" post="(ranging between 10−7 and 10−5) may appear low at"/>
 <result pre="of per-infection detection probability, while only about 10% of all" exact="infections" post="are estimated to lead to severe disease [18]. Secondly,"/>
 <result pre="10% of all infections are estimated to lead to severe" exact="disease" post="[18]. Secondly, the symptoms associated with mild or even"/>
 <result pre="[18]. Secondly, the symptoms associated with mild or even severe" exact="yellow fever" post="infections are wide and non-specific. This leads to cases"/>
 <result pre="the symptoms associated with mild or even severe yellow fever" exact="infections" post="are wide and non-specific. This leads to cases being"/>
 <result pre="leads to cases being frequently confused with severe malaria, leptospirosis," exact="viral hepatitis" post="or infections with other flaviviruses. Thirdly, our under-reporting estimates"/>
 <result pre="to cases being frequently confused with severe malaria, leptospirosis, viral" exact="hepatitis" post="or infections with other flaviviruses. Thirdly, our under-reporting estimates"/>
 <result pre="being frequently confused with severe malaria, leptospirosis, viral hepatitis or" exact="infections" post="with other flaviviruses. Thirdly, our under-reporting estimates constitute an"/>
 <result pre="(1984–2013). Regional capacities for laboratory confirmation of diagnostic was quite" exact="limited" post="over a large part of this time period [21]."/>
 <result pre="During this time period, official case detection reported the virtual" exact="absence of" post="reported cases in some years [13], while the annual"/>
 <result pre="[21]. While the FOI model variant assumes a constant local" exact="infection" post="risk for those unvaccinated, the R0 model variant relies"/>
 <result pre="CVC and therefore suppresses transmission [26]. While for an epidemic" exact="disease" post="this might appear an unrealistic assumption, one can consider"/>
 <result pre="model variants were designed in order to converge in the" exact="absence of" post="vaccination. Thus, in large regions of Eastern Africa with"/>
 <result pre="equilibrium assumption did not yield to massive overestimation in the" exact="disease" post="burden for low-transmission settings. Neither model variant completely captures"/>
 <result pre="Neither model variant completely captures the epidemic character of the" exact="disease" post="driven by rapid depletion of susceptible hosts during explosive"/>
 <result pre="explosive outbreaks, slow host renewal in inter-epidemic periods and sporadic" exact="disease" post="reintroductions. By design, these models are also unable to"/>
 <result pre="models are also unable to account for short-term changes in" exact="disease" post="transmission that could have resulted from recent changes in"/>
 <result pre="appeared to disregard several recent large-scale campaigns in West and" exact="Central" post="Africa [15]. Uncertainty in vaccination coverage is not directly"/>
 <result pre="may be propagated in the vaccine efficacy parameter. Indeed, the" exact="posterior" post="distribution of vaccine efficacy is much wider than the"/>
 <result pre="to be more sensitive to vaccine coverage. Lastly, in the" exact="absence of" post="more detailed data, vaccination activities were often assumed to"/>
 <result pre="compared with past work. We captured spatial heterogeneity in the" exact="disease" post="using a statistical rather than a mechanistic approach. Our"/>
 <result pre="does not explicitly represent the spatial distribution of vectors nor" exact="disease" post="reservoirs unlike Shearer et al’s model [10]. However, the"/>
 <result pre="calibrated against serological data that captures the whole spectrum of" exact="disease" post="severity. Other YF burden estimates stem from models calibrated"/>
 <result pre="to under-reporting and misdiagnosis. For instance, the Global Burden of" exact="Disease" post="estimates for 2016 around 5,000 YF-deaths in Africa, which"/>
 <result pre="around 5,000 YF-deaths in Africa, which is near to the" exact="lower" post="bound of our R0 model estimates. Lastly, the development"/>
 <result pre="from the sylvatic cycle to urban inter-human transmission [5]. Renewed" exact="disease" post="control strategies thus need to account for this change"/>
 <result pre="countries for PMVCs [34]. Supporting information S1 Table Presence or" exact="absence of" post="any reported yellow fever event between 1984 and 2013"/>
 <result pre="Supporting information S1 Table Presence or absence of any reported" exact="yellow fever" post="event between 1984 and 2013 at the first sub-national"/>
 <result pre="and 2013 at the first sub-national administrative level in 34" exact="African" post="countries. (CSV) LINK Click here for additional data file."/>
 <result pre="data file. S1 Fig Observed versus predicted presence/absence of any" exact="yellow fever" post="reported event between 1984 and 2013. A: Presence (red)"/>
 <result pre="prediction for probability of report for the R0 model. GLM:" exact="Generalized" post="Linear Model. Maps were produced from GADM version 2.0."/>
 <result pre="for probability of report for the R0 model. GLM: Generalized" exact="Linear" post="Model. Maps were produced from GADM version 2.0. (DOCX)"/>
 <result pre="model variants. A: coefficient of variation of the force of" exact="infection" post="estimates; B: coefficient of variation of the R0 estimates."/>
 <result pre="Click here for additional data file. S5 Fig Comparison of" exact="yellow fever" post="burden estimates over time between both model versions across"/>
 <result pre="Click here for additional data file. S6 Fig Comparison of" exact="yellow fever" post="burden estimates over time between both model versions across"/>
 <result pre="for granting access to epidemiological data. References References 1collab: WHO." exact="Yellow fever" post="in Africa and the Americas, 2016. Wkly Epidemiol Rec"/>
 <result pre="Epidemiol Rec WER. 2016;91: 181–192.27066609 5collab: World Health Organization. Eliminate" exact="Yellow fever" post="Epidemics (EYE): a global strategy, 2017–2026. Wkly Epidemiol Rec."/>
 <result pre="28429585 6KraemerMUG, FariaNR, ReinerRC, GoldingN, NikolayB, StasseS, et al.Spread of" exact="yellow fever" post="virus outbreak in Angola and the Democratic Republic of"/>
 <result pre="Infect Dis. 201610.1016/S1473-3099(16)30513-828017559 7ZhaoS, StoneL, GaoD, HeD. Modelling the large-scale" exact="yellow fever" post="outbreak in Luanda, Angola, and the impact of vaccination."/>
 <result pre="2018;12: e000615810.1371/journal.pntd.000615829338001 8RogersDJ, WilsonAJ, HaySI, GrahamAJ. The global distribution of" exact="yellow fever" post="and dengue. Adv Parasitol. 2006;62: 181–220. 10.1016/S0065-308X(05)62006-416647971 9GarskeT, Van"/>
 <result pre="10.1016/S0065-308X(05)62006-416647971 9GarskeT, Van KerkhoveMD, YactayoS, RonveauxO, LewisRF, StaplesJE, et al.Yellow" exact="Fever" post="in Africa: Estimating the Burden of Disease and Impact"/>
 <result pre="StaplesJE, et al.Yellow Fever in Africa: Estimating the Burden of" exact="Disease" post="and Impact of Mass Vaccination from Outbreak and Serological"/>
 <result pre="10ShearerFM, LongbottomJ, BrowneAJ, PigottDM, BradyOJ, KraemerMUG, et al.Existing and potential" exact="infection" post="risk zones of yellow fever worldwide: a modelling analysis."/>
 <result pre="BradyOJ, KraemerMUG, et al.Existing and potential infection risk zones of" exact="yellow fever" post="worldwide: a modelling analysis. Lancet Glob Health. 2018;010.1016/S2214-109X(18)30024-X29398634 11World"/>
 <result pre="a modelling analysis. Lancet Glob Health. 2018;010.1016/S2214-109X(18)30024-X29398634 11World Health Organization." exact="Yellow fever" post="key facts. 1 May 2018. http://www.who.int/en/news-room/fact-sheets/detail/yellow-fever 12FariaNR, KraemerMUG, HillSC,"/>
 <result pre="de JesusJG, AguiarRS, IaniFCM, et al.Genomic and epidemiological monitoring of" exact="yellow fever" post="virus transmission potential. Science. 2018; eaat7115. 10.1126/science.aat711530139911 13MonathTP, VasconcelosPFC."/>
 <result pre="fever virus transmission potential. Science. 2018; eaat7115. 10.1126/science.aat711530139911 13MonathTP, VasconcelosPFC." exact="Yellow fever." post="J Clin Virol. 2015;64: 160–173. 10.1016/j.jcv.2014.08.03025453327 14AndersonR, MayRM. Infectious"/>
 <result pre="Yellow fever. J Clin Virol. 2015;64: 160–173. 10.1016/j.jcv.2014.08.03025453327 14AndersonR, MayRM." exact="Infectious" post="Diseases of Humans: Dynamics and Control. 2nd ednOxford University"/>
 <result pre="fever. J Clin Virol. 2015;64: 160–173. 10.1016/j.jcv.2014.08.03025453327 14AndersonR, MayRM. Infectious" exact="Diseases" post="of Humans: Dynamics and Control. 2nd ednOxford University Press;"/>
 <result pre="FergusonN, et al.POLICI: A web application for visualising and extracting" exact="yellow fever" post="vaccination coverage in Africa. Vaccine. 2019;37: 1384–1388. 10.1016/j.vaccine.2019.01.07430770224 16JeanK,"/>
 <result pre="FergusonNM, GarskeT. A Meta-Analysis of Serological Response Associated with Yellow" exact="Fever" post="Vaccination. Am J Trop Med Hyg. 2016;95: 1435–1439. 10.4269/ajtmh.16-040127928091"/>
 <result pre="10.4269/ajtmh.16-040127928091 17GotuzzoE, YactayoS, CórdovaE. Efficacy and duration of immunity after" exact="yellow fever" post="vaccination: systematic review on the need for a booster"/>
 <result pre="18JohanssonMA, VasconcelosPFC, StaplesJE. The whole iceberg: estimating the incidence of" exact="yellow fever" post="virus infection from the number of severe cases. Trans"/>
 <result pre="StaplesJE. The whole iceberg: estimating the incidence of yellow fever" exact="virus infection" post="from the number of severe cases. Trans R Soc"/>
 <result pre="The whole iceberg: estimating the incidence of yellow fever virus" exact="infection" post="from the number of severe cases. Trans R Soc"/>
 <result pre="Soc Trop Med Hyg. 2014;108: 482–487. 10.1093/trstmh/tru09224980556 19WHO, UNICEF. Yellow" exact="Fever" post="Initiative Joint WHO and UNICEF 2010 Progress Report. Geneva,"/>
 <result pre="Med Hyg. 2014;108: 482–487. 10.1093/trstmh/tru09224980556 19WHO, UNICEF. Yellow Fever Initiative" exact="Joint" post="WHO and UNICEF 2010 Progress Report. Geneva, Switzerland: World"/>
 <result pre="burden of dengue. Nature. 2013;496: 504–507. 10.1038/nature1206023563266 21World Health Organization." exact="Yellow fever" post="vaccine. Wkly Epidemiol Rec. 2003; 349–359. 22KwagonzaL, MasiiraB, Kyobe-BosaH,"/>
 <result pre="349–359. 22KwagonzaL, MasiiraB, Kyobe-BosaH, KadoberaD, AtuheireEB, LubwamaB, et al.Outbreak of" exact="yellow fever" post="in central and southwestern Uganda, February-may 2016. BMC Infect"/>
 <result pre="2016. BMC Infect Dis. 2018;18: 54810.1186/s12879-018-3440-y30390621 23BagcchiS. Looking back at" exact="yellow fever" post="in Angola. Lancet Infect Dis. 2017;17: 269–270. 10.1016/S1473-3099(17)30064-628244394 24GaythorpeKAM,"/>
 <result pre="269–270. 10.1016/S1473-3099(17)30064-628244394 24GaythorpeKAM, JeanK, CibrelusL, GarskeT. Quantifying model evidence for" exact="yellow fever" post="transmission routes in Africa. PLOS Comput Biol. 2019;15: e100735510.1371/journal.pcbi.100735531545790"/>
 <result pre="911–916. 10.1093/cid/cir00721427399 27ShearerFM, MoyesCL, PigottDM, BradyOJ, MarinhoF, DeshpandeA, et al.Global" exact="yellow fever" post="vaccination coverage from 1970 to 2016: an adjusted retrospective"/>
 <result pre="retrospective analysis. Lancet Infect Dis. 2017;010.1016/S1473-3099(17)30419-X28822780 28collab: World Health Organization." exact="Yellow fever" post="in Africa and South America, 2015. Wkly Epidemiol Rec."/>
 <result pre="KerkhoveMV, et al.The seasonal influence of climate and environment on" exact="yellow fever" post="transmission across Africa. PLoS Negl Trop Dis. 2018;12: e000628410.1371/journal.pntd.000628429543798"/>
 <result pre="SantosE, Cardoso J daC, da SilvaLG, RabeloRM, Bicca-MarquesJC. Predicting Yellow" exact="Fever" post="Through Species Distribution Modeling of Virus, Vector, and Monkeys."/>
 <result pre="injuries, 1990–2015: a systematic analysis for the Global Burden of" exact="Disease" post="Study 2015. The Lancet. 2016;388: 1545–1602. 10.1016/S0140-6736(16)31678-627733282 33MonathTP, WoodallJP,"/>
 <result pre="solution. The Lancet. 2016;387: 1599–1600. 10.1016/S0140-6736(16)30195-7 34Global Strategy to Eliminate" exact="Yellow fever" post="Epidemics (EYE)—Document for SAGE. World Health Organisation; 2016 Sep."/>
</results>
